Fig. 3
From: Construction of a Vero cell line expression human KREMEN1 for the development of CVA6 vaccines
Vero-KRM1_#11 cells susceptible to replication of CVA6. (A) Representative cytopathic effect images of CVA6-infected Vero-KRM1_#11 cells or uninfected cells. Scale bar, 100 μm. (B) Representative fluorescence confocal images of CVA6-infected Vero-KRM1_#11 cells or uninfected cells. The primary antibody was CVA6-specific mAb 4D6 and the second antibody (green) was Alexa Fluor 488-conjugated goat anti-mouse IgG. The nuclei were stained with DAPI (blue). Scale bar, 50 μm. (C) Growth kinetics of CVA6-TW-00141 stain infection on RD, Vero and Vero-KRM1_#11 cells after infection at an MOI of 0.01. The virus samples were collected at the indicated time points and then titrated. The experiments were independently performed in triplicate. The values are expressed as the mean ± SD. Statistical significance was determined using unpaired Student’s t test. n.s., not significant. (D) Virus titers of CVA6-TW-00141 strain grown on Vero-KRM1_#11 cells from P3 to P20 generation of serial passages. The experiments were performed independently in triplicate. The values are expressed as the mean ± SD